Arcapta Quality Of Life Data For High Dose Cannot Overcome Efficacy Questions
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Pulmonary-Allergy Drugs Advisory Committee endorses approval of the 75 mcg dose of indacaterol but recommends against approval of Novartis' preferred 150 mcg dose of the chronic obstructive pulmonary disease drug.
You may also be interested in...
Novartis Finally Wins Arcapta Approval, Having Lost Battle On Desired Dose
Bronchodilator is approved for COPD at a 75 mcg dose, compared to 150 mcg and 300 mcg in Europe. Label nods to quality-of-life data.
Novartis Finally Wins Arcapta Approval, Having Lost Battle On Desired Dose
Bronchodilator is approved for COPD at a 75 mcg dose, compared to 150 mcg and 300 mcg in Europe. Label nods to quality-of-life data.
Novartis' Ilaris For Gout: FDA Questions Whether Symptom Relief Is Worth Risks
The agency will also ask its Arthritis Advisory Committee at a June 21 meeting whether the sponsor should explore lower doses for the interleukin-1 beta inhibitor.